Clinical Trial Update: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) [Phase 2]

View source ↗

Summary

This Phase 2 trial compares zilovertamab vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) against Polatuzumab vedotin plus R-CHP in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Zilovertamab vedotin (zilovertamab vedotin)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: RECRUITING